Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

医学 脱胶胰岛素 甘精胰岛素 低血糖 胰岛素 血糖性 糖尿病 内科学 2型糖尿病 早晨 随机对照试验 1型糖尿病 交叉研究 傍晚 内分泌学 儿科 安慰剂 替代医学 病理 物理 天文
作者
Carol Wysham,Anuj Bhargava,Louis Chaykin,Raymond de la Rosa,Yehuda Handelsman,Lone Troelsen,Kajsa Kvist,Paul Norwood
出处
期刊:JAMA [American Medical Association]
卷期号:318 (1): 45-45 被引量:200
标识
DOI:10.1001/jama.2017.7117
摘要

Importance

Hypoglycemia, a serious risk for insulin-treated patients with type 2 diabetes, negatively affects glycemic control.

Objective

To test whether treatment with basal insulin degludec is associated with a lower rate of hypoglycemia compared with insulin glargine U100 in patients with type 2 diabetes.

Design, Setting, and Participants

Randomized, double-blind, treat-to-target crossover trial including two 32-week treatment periods, each with a 16-week titration period and a 16-week maintenance period. The trial was conducted at 152 US centers between January 2014 and December 2015 in 721 adults with type 2 diabetes and at least 1 hypoglycemia risk factor who were previously treated with basal insulin with or without oral antidiabetic drugs.

Interventions

Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence.

Main Outcomes and Measures

The primary end point was the rate of overall symptomatic hypoglycemic episodes (severe or blood glucose confirmed [<56 mg/dL]) during the maintenance period. Secondary end points were the rate of nocturnal symptomatic hypoglycemic episodes (severe or blood glucose confirmed, occurring between 12:01amand 5:59am) and the proportion of patients with severe hypoglycemia during the maintenance period.

Results

Of the 721 patients randomized (mean [SD] age, 61.4 [10.5] years; 53.1% male), 580 (80.4%) completed the trial. During the maintenance period, the rates of overall symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 episodes per 100 patient-years of exposure (PYE) (rate ratio = 0.70 [95% CI, 0.61-0.80];P < .001; difference, −23.66 episodes/100 PYE [95% CI, −33.98 to −13.33]), and the proportions of patients with hypoglycemic episodes were 22.5% vs 31.6% (difference, −9.1% [95% CI, −13.1% to −5.0%]). The rates of nocturnal symptomatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 episodes/100 PYE (rate ratio = 0.58 [95% CI, 0.46-0.74];P < .001; difference, −7.41 episodes/100 PYE [95% CI, −11.98 to −2.85]), and the proportions of patients with hypoglycemic episodes were 9.7% vs 14.7% (difference, −5.1% [95% CI, −8.1% to −2.0%]). The proportions of patients experiencing severe hypoglycemia during the maintenance period were 1.6% (95% CI, 0.6%-2.7%) for insulin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargine U100 (McNemarP = .35; risk difference, −0.8% [95% CI, −2.2% to 0.5%]). Statistically significant reductions in overall and nocturnal symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the full treatment period.

Conclusions and Relevance

Among patients with type 2 diabetes treated with insulin and with at least 1 hypoglycemia risk factor, 32 weeks’ treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemia.

Trial Registration

clinicaltrials.gov Identifier:NCT02030600
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏应助zy采纳,获得10
1秒前
精明玲完成签到 ,获得积分10
2秒前
2秒前
乐乐完成签到,获得积分10
3秒前
VirSnorlax完成签到,获得积分10
3秒前
SciGPT应助LL采纳,获得10
3秒前
妖孽宇发布了新的文献求助10
4秒前
aa完成签到,获得积分20
4秒前
aaaa完成签到,获得积分10
4秒前
马香芦完成签到,获得积分10
5秒前
西红柿完成签到,获得积分10
6秒前
7秒前
懵懂的冬灵完成签到,获得积分10
7秒前
碧蓝可仁完成签到 ,获得积分10
8秒前
王拉拉完成签到 ,获得积分10
8秒前
西西完成签到,获得积分10
8秒前
深情安青应助mkmimii采纳,获得10
9秒前
上官若男应助小王采纳,获得10
9秒前
bkagyin应助旦皋采纳,获得10
9秒前
Orange应助欣欣采纳,获得10
10秒前
玄学大哥完成签到,获得积分10
10秒前
10秒前
10秒前
kk完成签到,获得积分10
10秒前
ww007完成签到,获得积分10
12秒前
科研通AI5应助hahaha123213123采纳,获得10
12秒前
misstwo完成签到,获得积分10
13秒前
研友_ZzrwqZ发布了新的文献求助10
13秒前
JY'完成签到,获得积分10
14秒前
一只小鲨鱼完成签到,获得积分10
15秒前
漂亮的哈密瓜完成签到,获得积分10
15秒前
量子星尘发布了新的文献求助10
15秒前
16秒前
LL发布了新的文献求助10
16秒前
苏苏完成签到,获得积分10
17秒前
17秒前
fabc5653219完成签到,获得积分10
18秒前
hkunyu完成签到 ,获得积分10
18秒前
jiao完成签到,获得积分10
19秒前
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029